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PROGNOSIS OF PRIMARY THYROID LYMPHOMA: DEMOGRAPHIC, CLINICAL
AND PATHOLOGIC PREDICTORS OF SURVIVAL
Amanda Graff-Baker, Sanziana A. Roman, Daniel C. Thomas, Robert Udelsman, Julie Ann Sosa, Section
of Endocrine Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT

The aim of this study is to assess associations between demographic, clinical and
pathologic characteristics of patients with primary thyroid lymphoma (PTL) and survival,
using both bivariate and multivariate analyses. We hypothesize that age, stage at
diagnosis, and histology will be independent predictors of survival after diagnosis of
PTL. Use of surgery to treat PTL will not improve survival.
PTL patients were identified in the SEER database. Bivariate (χ2, Kaplan-Meier,
and log rank) and multivariate (Cox proportional hazards) analyses were used to assess
the associations between patient characteristics and survival.
A total of 1,408 patients were identified. Overall, 98% had non-Hodgkin‟s
lymphoma; 68% had diffuse large B-cell, 10% follicular, 10% marginal zone, and 3%
small lymphocytic. A total of 88% had stage I or II disease. Median survival was 9.3
years. On bivariate analysis, older age, single marital status, stage II-IV disease, histology
(diffuse large B-cell, follicular, or other non-Hodgkin‟s), earlier year of diagnosis, lack of
prior malignancies, and no radiation or surgery predicted worse survival. Age ≥80 years,
stage IV disease, no radiation or surgery, and large B-cell or follicular histology predicted
worse prognosis in multivariate analysis.
Based on the analysis, we conclude that older age, advanced stage, histologic
subtype, and lack of radiation or surgical treatment are associated with worse survival.
Thyroid resection offers benefit only for patients with stage I disease.
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Introduction
Primary thyroid lymphoma (PTL) is a rare type of thyroid cancer. It has an estimated
incidence of 1-5% of thyroid malignancies and 2% of all extranodal lymphomas, with an
annual incidence of two per million (1-4). The vast majority of patients are diagnosed
with non-Hodgkin‟s lymphoma of B-cell origin; Hodgkin‟s lymphoma has been rarely
reported. A number of distinct histologic subtypes exist, each with unique diagnostic and
prognostic characteristics. Due to the rarity of this malignancy, the literature contains
only case reports and single institutional series evaluating PTL. This work represents the
first population-based study of PTL in the United States to examine associations among
patient demographic, pathologic, and clinical characteristics, including the extent of
thyroid resection, and overall and disease-specific survival.

Clinical presentation
The largest study of PTL in the United States to date encompassed 108 patients; it
found that PTL most commonly affects women (3:1 predominance) between the ages of
50 and 80 years, with a peak incidence in the late sixties (5). Patients typically present
with a rapidly growing thyroid mass and may experience hoarseness, stridor, or, less
commonly, dysphagia (6). The rate of thyroid enlargement tends to be more rapid in
those with PTL than in patients with other thyroid malignancies, with the exception of
anaplastic thyroid carcinoma (7). Patients may also present with “B symptoms”, such as
fever, night sweats, weight loss, pruritus, or all of the above. Patients with chronic
lymphocytic thyroiditis (Hashimoto‟s thyroiditis) are at increased risk of developing
PTL. There is a particularly strong association between Hashimoto‟s thyroiditis and
marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT), with
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an estimated relative risk of 67 (8). At least one-half of patients diagnosed with PTL
have a clinical history of Hashimoto‟s thyroiditis, and an even larger number have either
immunologic or pathologic evidence of the disease, with a reported rate as high as 94% in
one study (5, 9, 10). Nonetheless, most patients with Hashimoto‟s thyroiditis do not
develop PTL. Hashimoto‟s thyroiditis is strongly linked to human leukocyte antigen
(HLA) haplotype in certain populations, but recent investigations have not found a
similar HLA association for patients with PTL (11).

Histologic subtypes
Diffuse large B-cell lymphoma
PTL can be classified by histologic subtype. The most common of these subtypes
is diffuse large B-cell lymphoma (DLBCL), which accounts for approximately two-thirds
of cases (5). In some patients, DLBCL may arise from a preexisting MALT lymphoma,
and a component of MALT lymphoma can be seen in one-third of patients with DLBCL
(9). In terms of cellular immunophenotype, thyroid DLBCLs are CD20 positive, and the
majority are B-cell lymphoma (Bcl)-6 positive. Approximately half are Bcl-2 positive;
CD5, CD10, and CD23 are usually negative (9).
The most aggressive of the histologic subtypes, DLBCL is associated with the
worst prognosis and is an independent predictor of death from PTL (5). Positive
cytoplasmic staining for nm23-H1 protein and the nongerminal center B-cell type are
associated with a poor prognosis (9).
Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue
The second most common form of PTL, MALT is an indolent, low-grade
malignancy. Diagnostic features of thyroid MALT include lymphoepithelial lesions
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(LEL), reactivation germinal centers, and frequent plasmacytic differentiation. The
utility of LELs as a diagnostic feature of extranodal MALT lymphoma has been
questioned due to the presence of LELs in other histologic subtypes, but a recent sitespecific analysis reveals that LELs are found in 100% of thyroid MALT, indicating that
their presence is important for diagnosis (12). The presence of immunoglobulin light
chain, CD20, and Bcl-2 are expected, as are the absence of CD5, CD10, and CD23 (13).
Histologic similarities between thyroid MALT and follicular lymphoma and the
frequent association with Hashimoto‟s thyroiditis present diagnostic challenges (12, 14).
Distinguishing MALT from plasma cell neoplasms can be accomplished with expanded
immunostaining panels; immunoglobulin-M heavy chain staining in the plasma cell
component strongly supports the diagnosis of MALT (12). Prominent plasma cell
differentiation, follicular colonization, and presence of LELs may be found in
Hashimoto‟s thyroiditis and PTL, but the diagnosis of MALT can be made on the basis of
the presence of centrocyte-like cells on immunohistochemistry and clonal band on PCR
for the immunoglobulin heavy chain (14).
Multiple series that evaluated the histologic subtypes of PTL have reported that
patients with MALT have longer disease-specific survival than those with DLBCL,
although these disparities have not achieved statistical significance in all studies (5, 6, 15)
MALT more frequently presents in stage I than DLBCL (15). MALT patients respond
well to treatment and are significantly more likely to achieve complete remission when
compared to patients with DLBCL (15).
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Follicular lymphoma
Thyroid follicular lymphoma is widely reported to be less common than MALT.
Due to its rarity, the clinicopathologic features of thyroid follicular lymphoma have only
recently been characterized (16). Thyroid follicular lymphomas have neoplastic follicles
with typical follicular lymphoma morphology contained within a destructive atypical
lymphoid infiltrate. The interfollicular cells are small centrocytic cells, and LELs are
found in all cases. Immunohistochemistry commonly shows expression of Bcl-6, CD10
or both within the interfollicular cells. Bcl-2-positive thyroid follicular lymphoma is
associated with disseminated disease, whereas Bcl-2-negative neoplasms are more likely
to be localized. Follicular lymphoma can be distinguished from MALT by the expression
of Bcl-6, the presence of areas with typical follicular lymphoma architecture, and the lack
of immunoglobulin heavy chain expression (16).
Other
A number of other histologic subtypes of PTL have been reported, all at very low
rates. Hodgkin‟s lymphoma, small lymphocytic lymphoma, and plasmacytoma each
represent less than 5% of PTL, whereas T-cell, mantle cell, Burkitt‟s, and lymphoblastic
histologies are found in less than 1% of cases (3, 17-19)

Pathogenesis
Theories describing the molecular pathogenesis of PTL have been based on the
association between Hashimoto‟s thyroiditis and PTL. It has been postulated that the
chronic antigenic stimulation and proliferation of lymphoid tissue in Hashimoto‟s
thyroiditis creates cells that are susceptible to neoplastic transformation, leading to PTL.
Recent work by Moshynska et al. (20) supports this theory, by showing clonal similarity
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in immunoglobulin heavy chain gene rearrangement sequences in the clonal bands of
Hashimoto‟s thyroiditis and subsequently developed PTL.
The theory of antigenic stimulation does not explain the pathogenesis of PTL
entirely, as demonstrated by Takakuwa et al. (21). Aberrant somatic hypermutation,
previously attributed to the development of multiple proto-oncogenes in other types of
DLBCL, was shown in this study to target thyroid DLBCL, MALT, and particularly
follicular lymphoma. Interestingly, the authors also found aberrant somatic
hypermutation in two patients of Hashimoto‟s thyroiditis, leading to them to propose that
aberrant somatic hypermutation may represent an early step in the process of thyroid
lymphomagenesis in patients with Hashimoto‟s thyroiditis.

Diagnosis
Despite its rarity, PTL should always be considered in the differential diagnosis of
rapidly growing goiter or thyroid nodules. Definitive diagnosis of PTL is not possible
based on history, physical examination, thyroid function tests, or imaging alone due to
the lack of specificity of any of these for lymphoproliferative disorders. Tissue is
necessary for confirmation.
Fine needle aspiration
Fine needle aspiration (FNA) biopsy is an excellent diagnostic test for thyroid
disorders as it is minimally invasive and can be performed in the office. Unfortunately,
the reported accuracy of FNA is not high enough to rely solely on this test for diagnosis.
This is largely due to the histopathological similarities between PTL and Hashimoto‟s
thyroiditis. The lack of marked nuclear atypia in PTL makes the cytological
differentiation between the lymphoid infiltrate of Hashimoto‟s thyroiditis and lymphoma
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difficult (14, 15, 22). Several series have reported accurate diagnosis of PTL using FNA
in 60% of patients who were later proven to have the malignancy (15, 23). Takano et al.
(22) proposed a diagnostic method for non-Hodkin‟s PTL in which the detection of a
monoclonal immunoglobin heavy chain gene in B cells is combined with aspiration
biopsy-nucleic acid diagnosis (ABND). ABND uses extracted nucleic acids from
leftover cells found within the needle after FNA to allow for the detection of various
malignancies using the relatively small number of cells available in the needle. This
technique seems promising, but it has not yet shown high enough sensitivity or specificity
to replace the current diagnostic techniques.
Core needle and surgical biopsy
Most patients with suspected PTL require either core needle or open surgical
biopsy for histopathological confirmation, classification of histologic subtype, and
chemotherapeutic treatment planning. In a small study of six patients, ultrasound-guided
core needle biopsy was shown to be safe and accurate, suggesting that it may be
considered a suitable alternative to open surgical biopsy (24). Nonetheless, the more
limited core biopsy specimen may not be representative of the entire tumor, particularly
in the case of coexisting MALT and DLBCL histologies. Thus, there continues to be a
role for surgical biopsy to ensure that aggressive histologies are not missed (14).
Pretreatment evaluation
A number of laboratory studies are useful in evaluating patients with PTL. In
addition to obtaining standard serologic chemistries, serum lactate dehydrogenase and β2
microglobulin levels may be checked, as they have prognostic implications for non-
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Hodgkin‟s lymphoma (25). Thyroid function tests may also be useful due to the high
incidence of hypothyroidism in patients with PTL.
Staging
PTL is staged based on the Ann Arbor staging criteria (26), with up to 90% of
patients presenting with early stage disease (5, 15). Stage IE (extranodal) PTL is defined
as lymphoma limited to the confines of the thyroid gland, stage IIE denotes spread
beyond the thyroid to regional lymph nodes, stage IIIE involves lymph nodes on both
sides of the diaphragm, and stage IVE indicates systemic dissemination. Prognosis varies
by stage at diagnosis; patients who present with higher stage disease far significantly
worse than those presenting at earlier stages (5, 6).
Imaging
Cervical ultrasound is a standard initial imaging study in patients with thyroid
disease and masses. PTL often presents as a pseudocystic, hypoechoic region that can be
mistaken for a benign cyst on sonography (24). Therefore, a clear diagnosis cannot be
made on ultrasound alone. However, the use of ultrasound is particularly valuable in
guiding appropriate FNA or core needle biopsies. Once the diagnosis of PTL has been
established, imaging of the entire body is necessary in order to stage the patient
accurately. Computed tomography (CT) of the head, neck, chest, abdomen, and pelvis
are commonly employed. The clinical utility of fluorodeoxyglucose-PET (FDG-PET)
scanning has been of recent interest (27). In patients with DLBCL, FDG-PET appears to
be a sensitive modality for assessing PTL and may lead to earlier identification of disease
recurrence than CT scan surveillance (28). FDG-PET scanning is potentially inaccurate
in patients with Hashimoto‟s thyroiditis, in whom inflammation causes diffusely
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increased thyroid uptake and false-positive results. FDG-PET is also of limited clinical
utility in patients with MALT because the low metabolic rate of the malignancy and the
high rates of concurrent Hashimoto‟s thyroiditis lead to difficulty in detecting residual or
recurrent disease.

Treatment
Appropriate treatment for patients with PTL depends on histologic subtype, as the
tumor grade and the efficacy of each treatment modality vary by subtype. Thirty years
ago, PTL was considered a surgical disease, but the introduction of effective
chemotherapeutic regimens has significantly changed the treatment paradigm since then.
Currently, chemotherapy or combined chemotherapy and locoregional radiation are the
mainstay of treatment for most histologic subtypes. A study of 50 patients evaluating
surgical trends in the management of thyroid lymphoma found that fewer patients
underwent thyroid resection for therapeutic purposes in the latter half of the 35-year
study period and that surgical thyroid resection had no impact on disease-free survival
(29).
Localized treatment
Regardless of histologic subtype, there is consensus that the role of locoregional
treatments, such as surgical excision and radiation, is limited to patients with stage I or II
disease. MALT and follicular lymphomas tend to follow a more indolent course and are
frequently treated locally with either surgical excision or radiotherapy. Thyroid resections
can be difficult in patients with PTL due to the inflammatory nature of thyroiditis and
possible extrathyroidal extension. Some patients may present with a solitary thyroid
nodule, which is only diagnosed as PTL after surgical resection. Anecdotal evidence
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supports the irradiation of patients with stage I follicular PTL, as this treatment may be
curative, but there are no definitive studies in the literature. In MALT lymphomas of the
head and neck, chemotherapy does not have a clear effect on either disease-specific or
relapse-free survival (13). Patients with indolent histologic subtypes do require close
long-term follow-up, as thyroid MALT may be associated with high rates of
dissemination and recurrence (13).
DLBCL was once treated primarily with surgical excision, but localized
treatments now play less of a role. The rarity of this malignancy has hindered the use of
randomized, controlled trials to study the efficacy of surgical excision in stage I disease.
Limited radiation does enter the treatment paradigm for patients with bulky disease, as
does the use of surgery in cases of airway obstruction. Acute airway compromise in
patients with DLBCL due to tumor compression or invasion of the trachea is rare, but can
be managed with tracheostomy or with tracheal stents (30).
Chemotherapeutic regimens
To date, no randomized, controlled trials evaluating the efficacy of chemotherapy
in PTL exist, but outcomes have been extrapolated from studies of extranodal nonHodgkin‟s lymphoma. These studies suggest that the use of chemotherapy, most
commonly CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), in patients
with extranodal lymphomas is both well tolerated and efficacious. Most PTL patients
who present with recurrent disease relapse at a distant site, further supporting the case for
systemic treatment, either with chemotherapy alone or with combined modality treatment
(31).
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The U.S. Food and Drug Administration (FDA) approval of rituximab for the
treatment of DLBCL has altered the chemotherapeutic approach to patients with PTL.
Approved in 2006 for first-line treatment, rituximab is a monoclonal B-cell antibody that
selectively binds to the CD20 antigen found on pre-B and mature B lymphocytes (32). In
patients with DLBCL, rituximab is approved for use with CHOP or other anthracyclinebased chemotherapy regimens. For patients with follicular lymphoma, rituximab
improves outcomes when used in conjunction with CHOP or CVP (cyclophosphamide,
vincristine, and prednisone) (33).
Recently, a large study of 1222 elderly patients aged 61 to 80 years compared the
outcomes of patients with nodal DLBCL treated with either six or eight cycles of
rituximab and CHOP or CHOP alone. The addition of rituximab led to significantly
improved event-free, progression-free, and overall survival (OS) when compared with
CHOP alone, but the additional two cycles of R-CHOP did not, suggesting that elderly
patients are best treated with six cycles of R-CHOP (34). As with previous advances in
chemotherapy, treatment data from nodal lymphoma have been extrapolated to PTL, and
many centers now treat DLBCL PTL patients with rituximab when appropriate.
In summary, PTL is a rare malignancy, with few studies available in the literature
that evaluate prognostic factors and significant ongoing controversy regarding optimal
treatment paradigms for the various histologic subtypes. This work is the first
population-based study of PTL in the United States, and aims to provide insight into the
demographic, clinical, and pathologic predictors of overall and disease-specific survival
in this malignancy.
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Statement of Purpose
The Surveillance, Epidemiology, and End Results (SEER) Program of the
National Cancer Institute (NCI) is an excellent source for evaluating the prognosis,
treatment and outcomes of cancer patients in the United States. The SEER database is
the only database of cancer patients in the U.S. that provides information on disease stage
at diagnosis and that allows for the calculation of survival rates for each stage (35).
Using data from the SEER database, this project will assess associations between
demographic, clinical and pathologic characteristics of patients with primary thyroid
lymphoma and their overall and disease-specific survival, using both bivariate and
multivariate analyses. To our knowledge, this work is the first population-based study of
PTL in the U.S. The hypotheses are as follows:
(1) Younger age, lower stage at diagnosis, and radiation treatment will be
independent predictors of improved survival after diagnosis of PTL.
(2) When comparing disease-specific survival, patients with the histologic
subtype DLBCL will have the worst disease-specific survival, and MALT will be
associated with the best disease-specific survival.
(3) In accordance with treatment recommendations, use of surgery in the
treatment of PTL will have declined from 1973 to 2005, while the use of other treatment
modalities will have increased over the same time period.

Methods
Patients with PTL were identified in the Surveillance, Epidemiology, and End
Results (SEER) database of the National Cancer Institute from 1973 to 2005. The SEER
database was started in 1973 with 9 sites and currently provides cancer incidence and
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survival data from 17 geographic regions (Alaska, Atlanta, greater California,
Connecticut, Detroit, rural Georgia, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana,
New Jersey, New Mexico, San Francisco-Oakland, San Jose/Monterey, Seattle-Puget
Sound, and Utah) representing approximately 26% of the U.S. population. Although the
population captured by the database is more urban than the overall population, it is
comparable in terms of income level and education (35).
The International Classification of Diseases for Oncology, Third Edition (ICD-O3) coding system was used to select patients from SEER with primary tumors originating
in the thyroid (ICD-O-3 code C73.9), and histology-specific codes (ICD-O-3 codes 95909758) were then used to identify those with PTL. All patients with active follow-up were
included. Patients examined at death or by autopsy, or who were not followed after the
diagnosis, were excluded.
Demographic information included gender, age at diagnosis, year of diagnosis,
geographic location, race, and marital status at diagnosis. Age at diagnosis was analyzed
as both a continuous and a categorical variable: age <45, 45-59, 60-69, 70-79, and ≥80.
Year of diagnosis was analyzed with the following categories: 1973-1987, 1988-1997,
and 1998-2005. Geographic location was classified as West, Midwest, Northeast and
South. Race was categorized as white, black or other. Marital status was categorized as
married, single/divorced/widowed, and unknown.
Clinical characteristics included number of other malignancies (none, 1, or ≥2)
and systemic symptoms (asymptomatic, „„B‟‟ symptoms and/or pruritus). Each patient‟s
unique SEER patient identification number was used to identify other malignancies in the
cohort of PTL patients that were also captured within the SEER database (number and
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type of lifetime malignancies, type of prior malignancies, and radiation for prior
malignancy). The number of malignancies prior to the diagnosis of thyroid lymphoma
represents the sequence of PTL in patient‟s lifetime history of malignancy, even if the
prior malignancy is not represented in the SEER database. Cause of death of patients
who died during follow-up was classified as lymphoma, other malignancy, non-malignant
medical illness, accident/injury, and other/unknown.
Treatment modality was analyzed (no surgery or radiation, radiation only, surgery
only, or both surgery and radiation), as was regional lymphadenectomy (none, limited,
modified radical, or radical) and the number of regional lymph nodes examined in
conjunction with surgery (none, 1, or >1). Site-specific surgical therapy codes were used
to more specifically categorize the type of operation into none (including patients
receiving incisional, needle, or aspiration biopsy only), local excision/partial lobectomy,
lobectomy, and near-total/total thyroidectomy. Patients who received external beam
radiation, with or without radioisotopes, or unspecified radiation therapy were
categorized as a single group; patients who only received radioisotopes were categorized
separately. SEER does not include information regarding use of chemotherapy;
therefore, this treatment modality could not be evaluated in our analysis. Due to the
limitations of the database, some clinical characteristics were analyzed over limited time
frames. Data for the type of operation and systemic symptoms were only available after
1988; data for regional lymphadenectomy was available only from 1998 to 2002.
Pathologic characteristics examined include histologic subtype and stage at
diagnosis. Histologic subtype was analyzed as follows: (1) diffuse large B-cell (DLBCL)
(ICD-O-3 9680-9684), (2) follicular (ICD-O-3 9690-9698), (3) MALT (ICD-O-3 9699),

14
(4) small lymphocytic (ICD-O-3 9670-9671), (5) Hodgkin‟s (ICD-O-3 9650-9652 and
9663-9667), and (6) other non- Hodgkin‟s, including mixed, diffuse B-cell (ICD-O-3
9675), mantle cell (ICD-O-3 9673), Burkitt‟s (ICD-O-3 9687), T-cell (ICD-O-3 97029714), lymphoblastic (ICD-O-3 9727), and plasmacytoma (ICD-O-3 9731-9734).
PTL is staged based on the Ann Arbor staging criteria (26). As described in
previous studies analyzing lymphoma using SEER (36), information on cancer stage
according to the Ann Arbor guidelines was used to analyze PTL stage at diagnosis from
1988 to 2005.
Summary statistics for the entire PTL cohort and for each histologic subtype were
obtained for all demographic, clinical, and pathologic characteristics. Variable trends
over time were analyzed using broad groups (1973-1987, 1988-1996, and 1997-2005) as
well as 3 year intervals. An analysis of variance (ANOVA) was used for continuous
variables, and the χ2 test was used for categorical variables. A bivariate analysis was
performed using the Kaplan-Meier method and log-rank test to identify significant
prognostic factors and calculate overall and disease-specific survival. The Cox
proportional hazards regression model was used to obtain hazard ratios for each
independent variable and to conduct multivariate analysis. The strength of association
between each variable and survival was reported as a hazard ratio (HR), as well as a 95%
confidence interval (CI). Tests were 2-sided, with statistical significance assumed at a pvalue of < 0.05. The Statistical Package for Social Sciences software version 16.0 (SPSS
Inc., Chicago, IL) was used for data analyses. SEER is a public data set that contains
deidentified information; therefore, Institutional Review Board exemption was obtained.
All coding of the database and statistical analyses were conducted by the author (Amanda
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Graff-Baker), with assistance on the bivariate and multivariate analysis provided by
Daniel Thomas, MPH.

Results
Summary statistics
A total of 1408 patients with primary thyroid lymphoma were identified over 32
years of follow-up in the SEER database, with a median follow-up of 3.75 yrs. Seventyfive percent of patients were female and 93% were white (Table 1). Nearly half of the
patients were from the West (48%), with the Midwest being the second-most represented
region (28%). Mean age at diagnosis was 66 years, with 24% of patients diagnosed
between ages 60 and 69 years and 28% diagnosed between ages 70 and 79 years. Men
were diagnosed at a younger age than women (63 vs. 68 years, respectively, p < 0.001).
There was no significant difference in age noted when comparing patients diagnosed with
higher and lower stage disease.
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Table 1. Demographic Characteristics of Patients with Primary Thyroid
Lymphoma, SEER 1973-2005
Histologic Subtype
All
Patients

DLBCL

MALT

Follicular

(n=1408)

(n=846)

(n=120)

(n=123)

Patient Characteristics

Small
lymphocytic Hodgkin's
(n=40)

(n=24)

Percent (%)
75

75

71

77

70

79

66.4 ±14.1

68.4 ±13.3

63.8 ±14.3

62.4 ±12.3

68.4 ±13.1

38.2 ±19.6

<45

7

5

8

8

2

67

45-59

23

20

28

31

28

21

60-69

24

24

24

32

20

0

70-79

28

31

22

24

30

8

>80

18

20

18

6

20

4

White

93

93

84

94

95

91

Black

1

2

0

0

0

9

Other

6

5

16

6

5

0

Married

58

55

63

72

67

58

Single/divorced

42

45

37

28

33

42

Female
Age (mean years ± SD)

Race

Marital status

SEER, Surveillance, Epidemiology, and End Results Program; SD, standard deviation; MALT, mucosa associated lymphoid tissue

Histologically, 98% of patients had non-Hodgkin‟s lymphoma. Of the entire
cohort, 68% had DLBCL, 10% follicular, 10% MALT, 3% mixed diffuse B-cell, 3%
small lymphocytic, 2% Hodgkin‟s, 1% plasmacytoma. Burkitt‟s, T-cell, mantle cell, and
lymphoblastic lymphomas each accounted for less than 1% patients. Age at diagnosis
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varied between histologic subtypes. Approximately one third of patients with DLBCL
were diagnosed between the ages of 70-79, with a mean age at diagnosis of 68.4. The
mean age at diagnosis for patients with MALT, follicular lymphoma and small
lymphocytic lymphoma was also in the 60‟s. In contrast, two-thirds of patients with
Hodgkin‟s lymphoma were <45 years old and the mean age at diagnosis for those with
Hodgkin‟s was 38 years, significantly younger than the mean age at diagnosis for any of
the other histologic subtypes (p <0.001).
Most patients (56%) had stage I disease at diagnosis (Table 2); 32% were
diagnosed with stage II disease, 2% were diagnosed with stage III disease and 11% were
diagnosed with stage IV disease. Forty percent of patients underwent both surgery and
radiation, 28% underwent surgery only, 18% were treated with radiation only, and 15%
received neither surgery nor radiation. 70% of patients found to have stage I disease
received surgery, compared with 60% of patients with stage II and 56% of patients with
stage III/IV disease (p <0.001). Older patients were less likely to receive surgery; 55% of
patients over 80 years received surgery, while 66% of patients younger than 45 years,
72% of patients between 45 and 59 years, 73 % of patients between 60 and 69 years, and
67% of patients between 70 and 79 years were operated upon (p <0.001). Operative
treatment employed regional lymphadenectomy in only 3%. From 1998 to 2002, the
number of regional lymph nodes examined during surgery was recorded for 308 patients,
with 10% having one lymph node examined, 5% having more than one, and a majority
(85%) having no lymph nodes examined. Patients who did not receive surgery after 1988
overwhelming did not do so because surgery was not recommended (97%). Radiation
was used in 58% of patients with stage I disease, 60% of patients with stage II disease,
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and 31% of patients with stage III/IV disease. External beam radiation, either with or
without additional radioactive isotopes, was used as treatment for 58% of patients. An
additional seven patients (0.5%) received therapy with radioactive isotopes only.

Table 2. Clinical and Pathologic Characteristics of Patients with Primary
Thyroid Lymphoma, SEER 1973-2005
Histologic Subtype
All
Patients

DLBCL

Patient Characteristics

MALT

Small
Follicular lymphocytic Hodgkin's

Percent (%)
(n=1400)

(n=840)

(n=119)

(n=122)

(n=40)

(n=24)

68

65

83

80

80

71

(n=682)

(n=406)

(n=98)

(n=73)

(n=20)

(n=9)

17

19

11

11

15

11

34

32

39

41

30

56

49

49

50

48

55

33

(n=272)

(n=245)

(n=55)

(n=31)

(n=9)

(n=6)

None

97

98

96

97

100

100

Limited

3

2

4

3

0

0

Modified radical

1

1

0

0

0

0

Radical

0

0

0

0

0

0

Reason for no surgery

(n=312)

(n=205)

(n=18)

(n=18)

(n=4)

(n=40)

Not recommended

97

97

94

100

100

75

Contraindicated

2

2

0

0

0

0

Refused

1

0

6

0

0

25

(n=1352)

(n=812)

(n=117)

(n=121)

(n=39)

(n=24)

59

58

55

55

56

71

Surgery performed

Type of Surgery
Local excision/partial
lobectomy
Lobectomy
Near-total/total
thyroidectomy
Lymphadenectomy

Radiation therapy used
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Histologic Subtype
All
Patients

DLBCL

Patient Characteristics

MALT

Small
Follicular lymphocytic Hodgkin's

Percent (%)
(n=1357)

(n=806)

(n=116)

(n=120)

(n=39)

(n=24)

No surgery or radiation

14.7

15

10

10

8

4

Radiation only

17.9

20

7

10

13

25

Surgery only

27.7

27

34

34

36

25

Surgery and radiation

39.7

38

48

46

44

46

Systemic symptoms

(n=598)

(n=386)

(n=57)

(n=53)

(n=13)

(n=12)

Asymptomatic

87

86

91

96

92

75

13

14

9

4

8

25

(n=1062)

(n=666)

(n=115)

(n=91)

(n=25)

(n=12)

I

56

54

72

46

52

42

II

32

33

24

42

40

58

III

2

2

1

4

0

0

IV

11

12

3

8

8

0

Died of PTL

20.5

23

4

19

13

13

Died during follow-up

46.7

49

18

37

60

21

Treatment

"B" symptoms and/or
pruritus
Stage

SEER, Surveillance, Epidemiology, and End Results Program; SD, standard deviation; MALT, mucosa associated lymphoid tissue

Patients with DLBCL were significantly less likely to receive surgery than
patients with MALT or with follicular lymphoma (p <0.001 for both). The percentage of
patients undergoing radiation treatment was similar for all histologic subtypes (58.5% for
DLBCL, 54.7% for MALT, 55.4% for follicular, and 56.4% for small lymphocytic), with
the exception of patients with Hodgkin‟s lymphoma. 70.8% of those patients received
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radiation. For all histologic subtypes, patients were more likely to receive both surgery
and radiation than they were to receive either surgery or radiation alone.
Regardless of histologic subtype, the majority of patients presented with stage I or
stage II disease. Patients with MALT were less likely to present with stage III or stage
IV disease than those with DLBCL (p <0.01) or follicular lymphoma (p <0.01). More
than 10% of patients with DLBCL and Hodgkin‟s presented with systemic symptoms.
Patients with DLBCL were significantly more likely to present with systemic symptoms
than those with follicular lymphoma (p <0.05). Very few patients with MALT died of
PTL (4.2%).
For 79% of patients, PTL was their only malignancy. Of those patients with other
lifetime malignancies, 236 were recorded elsewhere in the SEER database. Common
sites of other malignancies were breast (66 patients), colon (37 patients), prostate (30
patients), and lung (29 patients). Of the other malignancies documented in the database,
125 occurred prior to PTL. 29% of those patients received radiation as treatment for their
first malignancy.
The use of surgery for PTL has declined over time. 81% of patients underwent
surgery from 1973 to 1987, whereas 61% had surgery from 1997 to 2005. A similar trend
was observed for radiation, with 69% of patients receiving radiation from 1973 to 1987,
compared with 53% from 1997 to 2005. Over time, PTL was diagnosed in patients at an
earlier stage; 83% were found to have stage I or stage II disease from 1988 to 1990,
whereas 88% were diagnosed at those stages in 2003 to 2005.
Of the 658 patients who died during follow-up, 44% died from lymphoma,
whereas 35% died from a nononcologic cause. Cardiovascular and cerebrovascular
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disease were the most common causes of nononcologic death, accounting for 68% of
cases. An additional 13% of patients died from non-PTL malignancies; lung cancer was
the most common, accounting for 34% of these deaths. Among patients who died from
PTL, 58% succumbed within the first year after diagnosis and 88% within the first 5
years.

Kaplan-Meier analysis
Median overall survival of the cohort was 9.3 years. The 5-year overall survival
was 66% and the 5-year disease-specific survival was 79% (Fig 1). Older age (age ≥60),
single marital status, and more advanced stage were associated with decreased diseasespecific survival on bivariate analysis (Table 3). When stratified by stage, patients who
were diagnosed at a higher stage had a shorter disease-specific survival (Fig 2). Five
years after diagnosis, disease-specific survival was 86% for patients with stage I disease,
81% for patients with stage II disease, and 64% for patients with stage III or IV disease.
Receiving operative treatment or radiation was associated with improved survival.
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Figure 1. Overall and disease-specific survival from primary thyroid
lymphoma. SEER, 1973-2005.

This graph displays the Kaplan-Meier survival curves from PTL for overall and diseasespecific survival. Five-year overall survival from PTL was 66% and 5-year diseasespecific survival was 79%. Of those who succumbed to PTL, 58% died within the first
year.

Table 3. Demographic, Clinical, and Pathologic Characteristics with
Associated Hazard Ratios Based on Bivariate Analysis of Disease-Specific
Mortality in Patients with Primary Thyroid Lymphoma, SEER 1973-2005
Hazards Ratio
(95% CI)

Variable
Gender

p-value

Male

1

*

Female

1.33 (0.99-1.77)

NS
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Hazards Ratio
(95% CI)

Variable
AgeA

p-value

<45

1

*

45-59

1.28 (0.59-2.76)

NS

60-69

2.16 (1.03-4.52)

<0.05

70-79

3.27 (1.59-6.73)

0.001

≥80

6.67 (3.23-13.78)

<0.001

Married

1

*

Not married

1.83 (1.45-2.31)

<0.001

White

1

*

Black

1.45 (0.60-3.50)

NS

Other

0.73 (0.40-1.34)

NS

1973-1987

1

*

1988-1996

0.71 (0.53-0.94)

<0.05

1997-2005

0.58 (0.44-0.77)

<0.001

No surgery or radiation

1

*

Radiation only

0.63 (0.43-0.93)

<0.05

Surgery only

0.57 (0.40-0.81)

<0.01

Surgery and radiation

0.54 (0.39-0.75)

<0.001

Marital StatusA

Race

Year of DiagnosisA

TreatmentA
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Hazards Ratio
(95% CI)

Variable
Type of surgery

p-value

None

1

*

Local excision/partial lobectomy

0.82 (0.50-1.33)

NS

Lobectomy

0.49 (0.32-0.77)

<0.01

Near-total/total thyroidectomy

0.79 (0.57-1.10)

NS

I

1

*

II

1.41 (1.00-1.97)

<0.05

III

1.38 (0.44-4.39)

NS

IV

3.08 (2.12-4.47)

<0.001

None

1

*

1

0.60 (0.42-0.85)

<0.01

≥2

0.62 (0.30-1.25)

NS

Asymptomatic

1

*

"B" symptoms and/or pruritus

1.43 (0.82-2.49)

NS

MALT

1

*

Diffuse large B-cell

5.46 (2.25-13.28)

<0.001

Follicular

3.74 (1.42-9.84)

<0.01

Small lymphocytic

2.61 (0.76-9.03)

NS

Other non-Hodgkin‟s

3.92 (1.44-10.71)

<0.01

Hodgkin‟s

2.43 (0.58-10.17)

NS

StageA

Number of other cancersA

Systemic symptoms

Histologic SubtypeA

* reference variable; A included in multivariate analysis
SEER, Surveillance, Epidemiology, and End Results Program; 95% CI, 95%
confidence interval; NS, not significant; MALT, mucosa associated lymphoid tissue
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Figure 2. Disease-specific survival from primary thyroid lymphoma by
stage. SEER, 1988-2005

Kaplan-Meier analysis was used to generate disease-specific survival curves, stratified by
stage. When compared to patients with stage I disease, patients with stage II and stages
III/IV disease fared significantly less well (p <0.05 and p <0.001, respectively).

Older age at diagnosis was associated with shorter disease-specific survival (Fig
3). Disease-specific survival at 5 years was more than 90% for patients less than 60 years
old, compared with 57% for patients ≥80 years old. There was a significant difference in
disease-specific survival for patients whose conditions were diagnosed more than 20
years ago compared with those from the last 2 decades (Fig 4).
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Figure 3. Disease-specific survival from primary thyroid lymphoma by age
at diagnosis. SEER, 1973-2005.

Survival curves were generated based on age at diagnosis, and a relentless dose-response
was associated with each additional ten years of age. With age <45 as the reference, the
decrease in survival was significant for all age brackets over 60 (p <0.05 for age 60-69, p
<0.01 for age 70-79, p <0.001 for age ≥80.)
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Figure 4. Disease-specific survival from primary thyroid lymphoma by year
of diagnosis. SEER, 1973-2005.

Survival curves for year of diagnosis demonstrate a significant difference in survival for
patients diagnosed from 1973-1987 when compared with those diagnosed from 19881996 (p <0.05) and those diagnosed from 1997-2005 (p <0.001).

When stratified by stage, treatment with surgery and radiation or surgery alone
was associated with improved survival for stage I disease (p < 0.001 for both), whereas
radiation was associated with improved survival for stages I and II (p < 0.05 for both)
(Fig 5).
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Figure 5. Disease-specific survival from stage I primary thyroid lymphoma
by treatment. SEER, 1988-2005.

All three groups of patients receiving radiation or surgery had better survival than the no
surgery or radiation group (p<0.05 for radiation only, p<0.001 for surgery only, p<0.001
for radiation and surgery). There was no significant difference in prognosis when
comparing the three treatment groups. All patients in the no surgery or radiation group
who died from PTL did so within the first three years, so the disease-specific survival of
that group is unchanged thereafter.

All variables associated with disease-specific survival were also significant for
overall survival, with 2 exceptions. Female sex predicted worse overall survival, but it
was not significant for disease-specific survival. The number of malignancies was only
significant for disease-specific survival.
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Histologic subtype analysis
When stratified by histologic subtype, patients with DLBCL, follicular, and other
non-Hodgkin‟s lymphomas had worse disease-specific survival than those with MALT
lymphoma (Fig 6). Patients with DLBCL are five times more likely to die from PTL than
patients with MALT. The 5-year disease-specific survival rate was 75% for DLBCL,
87% for follicular, 86% for small lymphocytic, 83% for other non-Hodgkin‟s, and 96%
for MALT lymphoma. Disease-specific survival from MALT was significant when
compared to patients with DLBCL (p <0.001), follicular lymphoma (p <0.01), and other
non-Hodgkin‟s lymphoma (p <0.01). Overall survival for patients with MALT was
significantly better than for patients with DLBCL (p <0.001) and other non-Hodgkin‟s
lymphomas (p <0.05).
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Figure 6. Disease-specific survival from primary thyroid lymphoma by
histologic subtype. SEER, 1973-2005.

Kaplan-Meier survival curves for each histologic subtype demonstrate significant
differences in survival. Patients with MALT had the best disease-specific survival and
were used as the reference group. Patients with follicular lymphoma, other nonHodgkin‟s lymphoma, and DLBCL all had significantly worse survival (p <0.05, p <0.05,
and p <0.001, respectively).

For patients with DLBCL, age, marital status, treatment modality and stage at
diagnosis were significant factors affecting disease-specific survival. Age was also
significant predictor of survival for patients with MALT (p =0.001) and with Hodgkin‟s
lymphoma (p <0.001). The hazard ratio for disease-specific survival of patients with
DLBCL ≥ 80 years old was 5.2 when compared to patients <45 years old (p < 0.001).
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Marriage offered some protection in terms of survival from DLBCL, with a hazard ratio
of 1.6 for single patients (p <0.001).
Just as in the overall analysis, DLBCL patients receiving surgery and/or radiation
had a significantly better disease-specific survival than patients who did not receive either
intervention. DLBCL patients who received neither surgery nor radiation had a 5-year
disease-specific survival of 58.7%; less than one-quarter of patients who received surgery
and/or radiation for DLBCL had died from PTL at five years (5-year disease-specific
survival: 79.9% for radiation only, 74.8% for surgery only, 77.4% for surgery and
radiation). The specific type of surgery performed for DLBCL, however, was not
significant.
Treatment was also a significant indicator of disease-specific survival for patients
with follicular lymphoma. All three groups of patients receiving treatment with surgery
and/or radiation had hazard ratios of less than one, indicating improved survival when
compared to patients who did not receive either treatment; however, the analysis only
reached statistical significance for those patients who received both surgery and radiation
(p <0.05). Treatment was not a significant predictor of disease-specific survival on
bivariate analysis for any of the other histologic subtypes.
Five-year disease specific survival decreased with increased stage for patients
with DLBCL, MALT, follicular lymphoma, and other non-Hodgkin‟s lymphoma; these
decreases reached statistical significance only for DLBCL and MALT (Table 4). For
patients with DLBCL, only one in five patients diagnosed with stage I disease will
succumb within five years, whereas 40% of patients with stage III or stage IV disease
will die from PTL during that time.
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Table 4. Five-Year Disease-Specific Survival by Histologic Subtype and
Stage in Patients with Primary Thyroid Lymphoma, SEER 1988-2005
Histologic subtype

Disease-specific
survival (SE)

p-value

Diffuse large B-cell
Stage I (n=357)

81.7% (2.3%)

*

Stage II (n=217)

75.8% (3.3%)

NS

Stage III/IV (n=92)

60.4% (5.6%)

<0.001

Stage I (n=42)

94.3 % (3.9%)

*

Stage II (n=38)

91.0% (5.0%)

NS

Stage III/IV (n=11)

88.9% (10.5%)

NS

Stage I (n=83)

97.5% (1.7%)

*

Stage II (n=28)

95.8% (4.1%)

NS

Stage III/IV (n=4)

50.0% (35.4%)

<0.05

Stage I (n=13)

82.1% (11.7%)

*

Stage II (n=10)

100%

NS

Stage III/IV (n=2)

100%

NS

Stage I (n=32)

93.8% (4.3%)

*

Stage II (n=16)

92.3% (7.4%)

NS

Stage III/IV (n=8)

85.7% (13.2%)

NS

Stage I (n=5)

75.0% (21.7%)

*

Stage II (n=7)

100%

NS

Stage III/IV (n=0)

--

NS

Follicular

MALT

Small lymphocytic

Other non-Hodgkin’s

Hodgkin’s

* reference variable
SEER, Surveillance, Epidemiology, and End Results Program; SE,
standard error; NS, not significant; MALT, mucosa associated lymphoid
tissue
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When disease-specific survival for each histologic subtype was assessed based on
stage and treatment modality, treatment with surgery and/or radiation were associated
with improved survival for patients with stage I DLBCL, small lymphocytic, and MALT
histologies. Stage II DLBCL treated with radiation had a better prognosis than stage II
DLBCL treated with neither surgery nor radiation (p < 0.05); treatment of stage II
DLBCL with surgery, either with or without radiation, was not associated with improved
prognosis. There were no other significant associations between histologic subtype and
treatment modality for stages II, III, and IV.

Multivariate analysis
Age, treatment modality, PTL stage, and histologic subtype remained significant
predictors of disease-specific survival in multivariate analysis (Table 5). Age ≥80
remained an independent predictor of decreased survival (p <0.001). Patients with stage
IV disease were 2.2 times more likely to die than those with stage I (p <0.001). All
treatment groups did better than the no surgery or radiation group. Compared with
patients with MALT lymphoma, patients with DLBCL were nearly 5 times more likely to
die (p <0.01), and patients with follicular histology were 3.5 times more likely to die (p <
0.05).
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Table 5. Demographic, Clinical, and Pathologic Characteristics with
Associated Hazards Ratios Based on Multivariate Analysis of DiseaseSpecific Mortality in Patients with Primary Thyroid Lymphoma, SEER
1988-2005
Variable

Hazards Ratio
(95% CI)

p-value

Age
<45

1

*

46-59

0.65 (0.24-1.76)

NS

60-69

1.03 (0.41-2.63)

NS

70-79

2.18 (0.91-5.25)

NS

≥80

4.57 (1.91-10.96)

0.001

No surgery or radiation

1

*

Radiation only

0.43 (0.26-0.73)

<0.01

Surgery only

0.59 (0.38-0.92)

<0.05

Surgery and radiation

0.53 (0.35-0.80)

<0.01

I

1

*

II

1.35 (0.94-1.95)

NS

III

1.76 (0.55-5.71)

NS

IV

2.19 (1.44-3.34)

<0.001

Treatment

Stage
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Variable

Hazards Ratio
(95% CI)

p-value

Histologic Subtype
MALT

1

*

Diffuse large B-cell

4.87 (1.79-13.26)

<0.01

Follicular

3.55 (1.15-10.96)

<0.05

Small lymphocytic

1.78 (0.33-9.73)

NS

Other non-Hodgkin‟s

1.89 (0.50-7.12)

NS

Hodgkin‟s

3.89 (0.40-37.71)

NS

* reference variable
SEER, Surveillance, Epidemiology, and End Results Program; 95% CI, 95%
confidence interval; NS, not significant; MALT, mucosa associated lymphoid tissue

Discussion
PTL is a rare malignancy, with an estimated annual incidence similar to that of
anaplastic thyroid cancer (3). To our knowledge, this study represents the first
population-level analysis of patients with this disease. PTL most commonly affects white
women over 60 years old, and most patients are found to have stage I disease. DLBCL is
the most common histology and it carries the worst prognosis. The use of surgery and
radiation for PTL has declined over time, although a majority of patients continue to
receive both surgery and radiation. PTL is more likely to be diagnosed at an earlier stage
now than it was 20 years ago. Approximately half of the patients died within 10 years of
diagnosis, but less than half of those died from PTL. In our multivariate analysis, age
≥80 years, advanced PTL stage, lack of radiation or surgical treatment, and DLBCL and
follicular histology were independently associated with decreased disease-specific
survival.
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To date, published analyses of PTL have been limited by small sample size,
leading to discrepancies in the reported prevalence of histologic subtypes, overall and
disease-specific survival, and significant prognostic indicators. Prior to this analysis, the
largest study of PTL in the United States analyzed 108 cases (5). In that study, 66% of
patients presented with stage I disease. Most patients had DLBCL, whereas
approximately one third of patients were found to have MALT lymphoma. Stage, but not
treatment, was associated with survival; no patients with stage I disease died during
follow-up. No significant differences in survival were found for stages II, III, or IV.
A literature review that included 211 patients concluded that combined
chemoradiation therapy should be the mainstay of treatment for PTL (37). Patients
treated with both radiation and chemotherapy had significantly lower rates of distant and
overall recurrence compared with those who received only one treatment modality. This
analysis was limited to radiation and chemotherapy and did not include operative
treatment. A more recent analysis of 50 PTL patients by Meyer-Rochow et al. (29) found
that 54% of patients presented with stage II disease, with significant differences in
survival between stages. No difference in disease-free survival was found when patients
underwent resection versus open biopsy, leading the authors to conclude that surgery
should be employed only to establish the diagnosis of PTL or to manage severe airway
obstruction.
Overall, the demographic characteristics of our large cohort were similar to those
described in smaller, single-institution series (5, 9, 17, 18, 29, 38-42). Our study is the
first to show a significant disparity between the sexes in the mean age at diagnosis, with
men diagnosed at a younger age. However, there was no significant difference between
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the sexes with regard to disease-specific survival. Prior studies have found that
approximately 90% of patients are found to have early stage PTL (5, 18, 29, 38). This is
consistent with the current study. The distribution of patients between stage I and stage II
varies widely in the literature, ranging from 31% to 71% for stage I (5, 18, 29, 38-41, 43,
44). Our finding of 56% of patients with stage I disease is within the reported range.
There is consensus that DLBCL is the most common histologic subtype (3, 4, 45, 46); in
our study, DLBCL accounted for 68% of all PTL. There is no such consensus about the
incidence of less common histologies. MALT lymphoma is thought to be the secondmost common histology in PTL; most studies have reported rates of 20% to 40% (5, 9,
42) Only 10% of our cohort had MALT and a larger percentage had follicular lymphoma
that has been reported in most studies (5, 18, 42).
Reported overall survival from PTL ranges from 56% to 90% (9, 31). Derringer
et al. (5) reported a 5-year disease-specific survival of 79%, with 90% of deaths occurring
within the first three years after diagnosis. Our findings are similar, with a 5-year
disease-specific survival of 79% and 80% of deaths occurring within the first 3 years.
While 5-year disease-specific survival for stage I has been reported to be as high as 100%
(5, 39), other studies have not found that stage I patients do so well (6, 31); in the current
study, 14% of patients with stage I PTL died within 5 years of their diagnosis.
Belal et al. (39) reported that age had no effect on overall or recurrence-free
survival; in contrast, DiBiase et al. (31) found that advanced age was associated with
shorter overall survival. In the current study, a dose-response association was observed
between increasing age and shorter disease-specific survival. Older age was associated
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with more aggressive histology; still, age remained an independent predictor of diseasespecific survival after adjustment for histology in our multivariate analysis.
Several studies have concluded that PTL stage and histology predict prognosis;
that is, patients examined at an earlier stage or with MALT lymphoma have the best
outcomes (5, 18, 29). These studies have relied on bivariate comparisons, rather than
multivariate analysis, to provide support for these conclusions, as none of the series have
been large enough to power a multivariate analysis. Studies that report significant
survival differences based on stage have concluded that patients with stage I disease fare
significantly better than those with stage IV (5, 6, 29); there is less consensus about
prognostic implications of stage II and stage III disease. Our multivariate analysis
indicated that patients with stage IV disease were twice as likely to die from PTL as those
with stage I disease, but found no significant differences in survival of patients with stage
I disease when compared to those with stage II or stage III disease.
Despite concluding that histologic subtype is an important factor in diseasespecific survival from PTL, few studies have been large enough to conduct statistical
analysis comparing the different histologic subtypes or to assess prognostic factors for
each histologic subtype. This is the first study encompassing a large enough number of
patients with PTL to allow for such analysis. We found that patients with DLBCL and
follicular lymphoma were more likely to present with advanced stage disease than those
with MALT. Patients with DLBCL were more likely to present with systemic symptoms
than those with follicular lymphoma. The bivariate analyses conducted for each
histologic subtype were most robust for DLBCL, where age, marital status, treatment and
stage were all found to be significantly associated with disease-specific survival from
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DLBCL. Disease-specific survival for patients with DLBCL and follicular lymphoma
was significantly worse when compared with MALT lymphoma in multivariate analysis,
thus corroborating prognostic value of histologic subtype for PTL.
In our multivariate analysis, the year of diagnosis was not associated with
survival, which indicated that patients whose conditions were diagnosed in 2005 did not
fare better than those whose conditions were diagnosed in 1988, despite considerable
changes in the treatment paradigm for PTL during the last 2 decades. Treatment analysis
in SEER was limited by a lack of chemotherapy data and by our inability to extrapolate
surgical intent from the database. Still, several treatment-related results were available.
Despite a growing consensus over the last decade that PTL is best treated by
chemotherapy and/or radiation, depending on the histologic subtype (29, 37, 45), 61% of
patients underwent surgery for PTL from 1997 to 2005. Possible reasons for surgical
resection include tumor debulking for advanced disease, definitive treatment for stage I,
or inappropriate operations. It is also possible that some patients underwent surgery for
other thyroid pathology, and the diagnosis of PTL was only appreciated in the
postoperative setting. Procedures used for the diagnosis of PTL and acquisition of tissue
for immunohistochemical studies prior to the enrollment in chemotherapeutic protocols,
such as incisional, needle, and aspiration biopsies, were not considered surgical
procedures in our analysis, thus eliminating the possibility that high rates of surgery seen
from 1997 to 2005 were a reflection of increased diagnostic testing.
There are no published randomized, controlled trials studying the efficacy of
chemotherapy for PTL; therefore, chemotherapy regimens have been extrapolated from
studies of extranodal lymphomas (45). Approved by the FDA after the conclusion of the
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study period in 2006 as a first-line therapy for non-Hodgkin‟s lymphoma, rituximab has
been used for off-label treatment of non-Hodgkin‟s PTL for the last several years. We
were unable to assess whether any patients captured in the SEER database were treated
with rituximab off-label. Patients with DLBCL at most centers receive 6-8 courses of RCHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) as
an initial treatment (18, 45). A single case report exists describing the treatment of PTL
with rituximab. This patient was diagnosed with stage IE DLBCL in the left thyroid lobe
after having a right lobectomy 10 years prior for medullary thyroid carcinoma. Treated
with six courses of R-CHOP, the thyroid mass completely disappeared, and the patient
achieved complete remission for the 34 months of follow-up (47).
Controversy still exists about the role of thyroid surgery for early stage disease (3,
4, 37, 44, 45). Our results suggest that surgery and radiation are associated with
improved disease-specific survival for patients with stage I PTL. A study of 62 patients
from the Mayo Clinic concluded that thyroidectomy with adjuvant chemotherapy
provided long-term cure for PTL contained within the thyroid capsule (48). Other studies
provide retrospective evidence for the use of single-modality therapy with surgery or
radiation for indolent forms of PTL such as MALT (5, 45). Our data supported an
association between surgery and/or radiation and the improved survival for patients with
stage I MALT, DLBCL, and small lymphocytic histologies. The recurrence rates for PTL
have been shown to be reduced by chemotherapy, but we could not test this finding in
SEER.
Limitations of this study include those inherent to any analysis using a large
database, such as coding errors, although SEER has been well validated. SEER does not
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include imaging or central pathologic review. Information regarding chemotherapy is not
available; therefore, the decline in use of surgery and radiation and the rise in the
percentage of patients receiving neither surgery nor radiation over time might reflect
increasing use of chemotherapy. SEER does not include information about patient
comorbidities, so the number of primary tumors was the only available proxy for patient
(oncologic) comorbidity. SEER also does not include recurrence or reoperation rates, so
measurable outcomes were limited to overall and disease-specific survival.
In conclusion, this represents the largest population-based study of PTL published
to date. Patient age, PTL stage and histology, and treatment modality are independently
associated with survival. The paucity of data from large studies adequately powered to
examine a relatively rare clinical entity such as PTL implies the need for additional
research. We propose the creation of a retrospective/prospective multi-institutional
thyroid lymphoma database that incorporates centers with experience in oncology,
endocrinology, and thyroid surgery. In particular, future study should be committed to
examining the role of operative treatment for early stage PTL. Given the importance of
early diagnosis for improved survival, education of the public as well as of primary care
physicians, endocrinologists, and oncologists should be emphasized.
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